ARRIVENT BIOPHARMA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ARRIVENT BIOPHARMA, INC. (AVBP) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $40.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- ARRIVENT BIOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $40.40M, a 63.56% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $24.70M, a 2.49% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $24.10M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $40.40M 10-K · filed 2026-03-05 |
| 2024-12-31 | $24.70M 10-K · filed 2026-03-05 |
| 2023-12-31 | $24.10M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |